AIxCrypto Holdings, Inc. 10-K

Item 7A. Quantitative and Qualitative Disclosures about Market Risk. We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item. 31 Item 8. Consolidated Financial Statements and Supplementary Data INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm (PCAOB ID: 23 ) 33 Consolidated Balance Sheets 35 Consolidated Statements of Operations and Comprehensive Loss 36 Consolidated Statements of Stockholders’ Equity 37 Consolidated Statements of Cash Flows 38 Notes to Consolidated Financial Statements 39 32 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of Qualigen Therapeutics, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Qualigen Therapeutics, Inc. (the “Company”) as of December 31, 2023 and December 31, 2022, the related consolidated statements of operations and comprehensive loss, stockholders’ equity (deficit) and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and December 31, 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America. Going Concern Uncertainty The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company’s current liquidity position and projected cash needs raise substantial doubt about its ability to continue as a going concern. Management’s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis for Opinion These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. Critical Audit Matter The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates. 33 Accounting for Financial Instruments – Modification of Convertible Debt with Warrants Critical Audit Matter Description As described in Note 8 to the consolidated financial statements, during the year ended December 31, 2023, the Company modified the conversion price and strike price of its convertible debenture and common stock purchase warrants, respectively. Further, the Company modified certain terms of its stock warrant agreements that were originally classified as liabilities enabling them to be classified as equity. We identified the accounting for the modification of this complex financial instrument as a critical audit matter. This includes both the evaluation of the various features as potential embedded derivatives and the determination of the respective fair value of the instruments and the embedded features, as well as the determination of the appropriate classification of warrants between equity and liabilities. The application of the accounting guidance applicable to issuing and modifying a complex financial instrument requires significant judgment. Determination of appropriate classification of warrants requires management’s judgments relating to the interpretations of relevant accounting guidance based on specific provisions of the warrant agreement. Accounting for the convertible notes and embedded conversion features requires management’s judgments related to initial and subsequent recognition of the debt and related features, use of a valuation model, and key inputs used in the selected valuation model. How We Addressed the Matter in Our Audit The primary procedures we performed to address this critical audit matter included: ● Inspecting the agreements associated with the transactions and evaluating management’s technical accounting analysis, including the application of the relevant accounting literature. ● Utilizing an auditor’s specialist to assist in assessing management’s analysis of the transaction, including (i) evaluating the contracts to identify relevant terms that affect the recognition of the financial instruments, (ii) assessing the appropriateness of conclusions reached by management, and (iii) reviewing the valuation model for derivatives, performing independent calculations, and examining the significant assumptions utilized in the valuation model. /s/ Baker Tilly US, LLP We have served as the Company’s auditor since 2018. San Diego, California April 5, 2024 34 QUALIGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS December 31, December 31, 2023 2022 ASSETS Current assets Cash $ 401,803 $ 3,165,985 Prepaid expenses and other current assets 764,964 1,366,704 Current assets of discontinued operations — 6,287,849 Total current assets 1,166,767 10,820,538 Property and equipment, net — 26,242 Other assets 866,481 — Non-current assets of discontinued operations — 8,236,711 Total Assets $ 2,033,248 $ 19,083,491 LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Current liabilities Accounts payable $ 2,222,983 $ 619,568 Accrued expenses and other current liabilities 560,006 864,559 Warrant liabilities 54,600 788,100 Warrant liabilities - related party — 2,834,547 Convertible debt - related party 1,299,216 60,197 Current liabilities of discontinued operations — 3,441,198 Total current liabilities 4,136,805 8,608,169 Non-current liabilities of discontinued operations — 1,708,732 Total liabilities 4,136,805 10,316,901 Commitments and Contingencies (Note 10) - - Stockholders’ equity (deficit) Qualigen Therapeutics, Inc. stockholders’ equity (deficit): Common stock, $ 0.001 par value; 225,000,000 shares authorized; 5,362,128 and 4,210,737 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively 43,262 42,110 Additional paid-in capital 114,655,565 110,528,050 Accumulated other comprehensive income — 50,721 Accumulated deficit ( 116,802,384 ) ( 103,385,172 ) Total Qualigen Therapeutics, Inc. stockholders’ equity (deficit) ( 2,103,557 ) 7,235,709 Noncontrolling interest — 1,530,881 Total Stockholders’ Equity (deficit) ( 2,103,557 ) 8,766,590 Total Liabilities & Stockholders’ Equity (Deficit) $ 2,033,248 $ 19,083,491 The accompanying notes are an integral part of these consolidated financial statements. 35 QUALIGEN THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS 2023 2022 For the Years Ended December 31, 2023 2022 EXPENSES General and administrative $ 6,095,607 10,274,600 Research and development 5,209,250 4,486,120 Total expenses 11,304,857 14,760,720 LOSS FROM OPERATIONS ( 11,304,857 ) ( 14,760,720 ) OTHER EXPENSE (INCOME), NET Gain on change in fair value of warrant liabilities ( 2,035,469 ) ( 907,203 ) Interest expense, net 1,524,722 34,397 Loss on voluntary conversion of convertible debt 1,077,287 — Loss on debt extinguishment 625,653 — Loss on fixed asset disposal 21,747 — Other income, net ( 38,994 ) — Total other expense (income), net 1,174,946 ( 872,806 ) LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES ( 12,479,803 ) ( 13,887,914 ) (BENEFIT) PROVISION FOR INCOME TAXES ( 4,793 ) 6,548 NET LOSS FROM CONTINUING OPERATIONS ( 12,475,010 ) ( 13,894,462 ) DISCONTINUED OPERATIONS Loss from discontinued operations, net of tax ( 683,008 ) ( 7,140,181 ) Loss on disposal of discontinued operations, net of tax ( 602,232 ) — LOSS FROM DISCONTINUED OPERATIONS ( 1,285,240 ) ( 7,140,181 ) NET LOSS ( 13,760,250 ) ( 21,034,643 ) Net loss attributable to non-controlling interest from discontinued operations ( 343,038 ) ( 2,394,100 ) Net loss attributable to Qualigen Therapeutics, Inc. $ ( 13,417,212 ) $ ( 18,640,543 ) Net loss per common share, basic and diluted - continuing operations $ ( 2.46 ) $ ( 3.62 ) Net loss per common share, basic and diluted - discontinued operations $ ( 0.19 ) $ ( 1.24 ) Weighted-average number of shares outstanding, basic and diluted 5,072,709 3,840,340 Other comprehensive loss, net of tax Net loss $ ( 13,760,250 ) $ ( 21,034,643 ) Foreign currency translation adjustment from discontinued operations 119,473 50,721 Other comprehensive loss ( 13,640,777 ) ( 20,983,922 ) Comprehensive loss attributable to noncontrolling interest from discontinued operations ( 304,735 ) ( 2,394,100 ) Comprehensive loss attributable to Qualigen Therapeutics, Inc. $ ( 13,336,042 ) $ ( 18,589,822 ) The accompanying notes are an integral part of these consolidated financial statements. 36 QUALIGEN THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY Shares Amount Paid-In Capital Comprehensive Income Accumulated Deficit Equity (Deficit) Noncontrolling Interest Equity (Deficit) Common Stock Additional Accumulated Other Comprehensive Total Qualigen Therapeutics, Inc. Stockholders’ Total Stockholders’ Shares Amount Paid-In Capital Income (Deficit) Accumulated Deficit Equity (Deficit) Noncontrolling Interest Equity (Deficit) Balance at December 31, 2022 4,210,737 $ 42,110 $ 110,528,050 $ 50,721 $ ( 103,385,172 ) $ 7,235,709 $ 1,530,881 $ 8,766,590 Voluntary conversion of convertible debt into common stock 841,726 842 1,111,740 — — 1,112,582 — 1,112,582 Redemptions of convertible debt into common stock 309,665 310 254,006 — — 254,316 — 254,316 Fair value of warrant modification for professional services — — 7,945 — — 7,945 — 7,945 Fair value of warrant reclassified from liabilities to equity — — 1,626,694 — — 1,626,694 — 1,626,694 Stock-based compensation — — 1,098,533 — — 1,098,533 9,297 1,107,830 Foreign currency translation adjustment — — 28,597 81,170 — 109,767 38,303 148,070 Deconsolidation of discontinued operations — — — ( 131,891 ) — ( 131,891 ) ( 1,235,443 ) ( 1,367,334 ) Net loss — — — — ( 13,417,212 ) ( 13,417,212 ) ( 343,038 ) ( 13,760,250 ) Balance at December 31, 2023 5,362,128 $ 43,262 $ 114,655,565 $ — $ ( 116,802,384 ) $ ( 2,103,557 ) $ — $ ( 2,103,557 ) Common Stock Additional Accumulated Other Total Qualigen Therapeutics, Inc. Total Shares Amount Paid-In Capital Comprehensive Income Accumulated Deficit Stockholders’ Equity Noncontrolling Interest Stockholders’ Equity Balance at December 31, 2021 3,529,018 $ 35,290 $ 101,274,073 $ — $ ( 84,744,629 ) $ 16,564,734 $ — $ 16,564,734 Balance 3,529,018 $ 35,290 $ 101,274,073 $ — $ ( 84,744,629 ) $ 16,564,734 $ — $ 16,564,734 Stock issued upon exercise of warrants 332,000 3,320 4,711 — — 8,031 — 8,031 Stock-based compensation — — 5,484,044 — — 5,484,044 — 5,484,044 Common stock and prefunded warrants issued for business acquisition 350,000 3,500 3,740,417 — — 3,743,917 3,882,225 7,626,142 Noncontrolling interest adjustments relating to Stock-based compensation and other — — ( 42,756 ) — — ( 42,756 ) 42,756 — Foreign currency translation adjustment — — — 50,721 — 50,721 — 50,721 Fair value of warrant modification for professional services — — 67,370 — — 67,370 — 67,370 Fair value of warrant modification for business acquisition — — 696 — — 696 — 696 Issuance of rounded shares as a result of the reverse stock split ( 281 ) — ( 505 ) — — ( 505 ) — ( 505 ) Net loss — — — — ( 18,640,543 ) ( 18,640,543 ) ( 2,394,100 ) ( 21,034,643 ) Balance at December 31, 2022 4,210,737 $ 42,110 $ 110,528,050 $ 50,721 $ ( 103,385,172 ) $ 7,235,709 $ 1,530,881 $ 8,766,590 Balance 4,210,737 $ 42,110 $ 110,528,050 $ 50,721 $ ( 103,385,172 ) $ 7,235,709 $ 1,530,881 $ 8,766,590 The accompanying notes are an integral part of these consolidated financial statements. 37 QUALIGEN THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS 2023 2022 For the Years Ended December 31, 2023 2022 CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ ( 13,760,250 ) $ ( 21,034,643 ) Loss from discontinued operations, net of tax ( 1,285,240 ) ( 7,140,181 ) Loss from continuing operations ( 12,475,010 ) ( 13,894,462 ) Adjustments to reconcile loss from continuing operations to net cash used in operating activities: Depreciation and amortization 4,495 12,165 Stock-based compensation 1,098,533 4,765,276 Change in fair value of warrant liabilities ( 2,035,469 ) ( 906,345 ) Loss on voluntary conversion of convertible debt 1,077,287 — Accretion of discount on convertible debt 1,469,640 — Loss on debt extinguishment 625,653 — Loss on disposal of fixed assets 21,747 — Fair value of warrant modification for professional services 7,945 67,370 Changes in operating assets and liabilities: Prepaid expenses and other assets ( 264,741 ) ( 126,985 ) Accounts payable 1,603,422 ( 43,440 ) Accrued expenses and other current liabilities ( 227,101 ) ( 472,441 ) Net cash used in operating activities - continuing operations ( 9,093,599 ) ( 10,598,862 ) Net cash provided by (used in) operating activities - discontinued operations ( 1,210,664 ) ( 2,648,679 ) Net cash used in operating activities ( 10,304,263 ) ( 13,247,541 ) CASH FLOWS FROM INVESTING ACTIVITIES: Net cash provided by (used in) investing activities - discontinued operations 4,215,943 ( 183,763 ) Net cash provided by (used in) investing activities 4,215,943 ( 183,763 ) CASH FLOWS FROM FINANCING ACTIVITIES: Net proceeds from warrant exercises — 7,173 Proceeds from issuance of convertible debt — 2,903,847 Payments on convertible notes payable ( 550,000 ) — Fractional share payments related to the reverse stock split — ( 505 ) Net cash (used in)/provided by financing activities - continuing operations ( 550,000 ) 2,910,515 Net cash used in financing activities - discontinued operations — — Net cash (used in) provided by financing activities ( 550,000 ) 2,910,515 Net change in cash and restricted cash ( 6,638,320 ) ( 10,520,789 ) Effect of exchange rate changes on cash and restricted cash — 22,639 Cash and restricted cash from continuing operations - beginning of period 3,165,985 9,174,383 Cash and restricted cash from discontinued operations - beginning of period 3,874,138 8,363,890 Less: cash and restricted cash from discontinued operations - end of period — ( 3,874,138 ) Cash from continuing operations - end of period $ 401,803 $ 3,165,985 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash paid during the year for: Interest $ — $ — Taxes $ 5,571 $ 5,571 NONCASH FINANCING AND INVESTING ACTIVITIES: Net transfers to equipment held for lease from inventory $ 83,281 $ — Fair value of warrant liabilities on date of exercise $ — $ 858 Redemption of convertible debt into common stock $ 254,316 $ — Voluntary conversion of convertible debt into common stock $ 1,112,582 $ — Fair value of warrant modifications pursuant to Securities Purchase Agreement $ — $ 9,439 Fair value of warrant modifications for business acquisition $ — $ 33,543 The accompanying notes are an integral part of these consolidated financial statements. 38 QUALIGEN THERAPEUTICS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 — ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES Organization Ritter Pharmaceuticals, Inc. (the Company’s predecessor) was formed as a Nevada limited liability company on March 29, 2004 under the name Ritter Natural Sciences, LLC. In September 2008, this company converted into a Delaware corporation under the name Ritter Pharmaceuticals, Inc. On May 22, 2020, upon completing a “reverse recapitalization” transaction with Qualigen, Inc., Ritter Pharmaceuticals, Inc. was renamed Qualigen Therapeutics, Inc. (the “Company”). Qualisys Diagnostics, Inc. was formed as a Minnesota corporation in 1996, reincorporated to become a Delaware corporation in 1999, and then changed its name to Qualigen, Inc. in 2000. Qualigen, Inc. was a wholly-owned subsidiary of the Company. On July 20, 2023, the Company sold all of the issued and outstanding shares of common stock of Qualigen, Inc. to Chembio Diagnostics, Inc. (“Chembio”), a wholly-owned subsidiary of Biosynex, S.A. (“Biosynex”). Following the consummation of this transaction, Qualigen, Inc. became a wholly-owned subsidiary of Chembio (see Note 5 – Discontinued Operations). On May 26, 2022, the Company acquired 2,232,861 shares of Series A-1 Preferred Stock of NanoSynex, Ltd. (“NanoSynex”) from Alpha Capital Anstalt (“Alpha”), a related party, in exchange for 350,000 reverse split adjusted shares of the Company’s common stock and a prefunded warrant to purchase 331,464 reverse split adjusted shares of the Company’s common stock at an exercise price of $ 0.001 per share. These warrants were subsequently exercised on September 13, 2022. Concurrently with this transaction, the Company also entered into a Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022, with NanoSynex (the “NanoSynex Funding Agreement”), to, among other things, provide for the further funding of NanoSynex, and purchased 381,786 shares of Series B preferred stock from NanoSynex for a total purchase price of $ 600,000 . The transactions resulted in the Company acquiring a 52.8 % interest in NanoSynex (the “NanoSynex Acquisition”). NanoSynex is a nanotechnology diagnostics company domiciled in Israel. On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex (the “NanoSynex Amendment”), which amended the NanoSynex Funding Agreement, to, among other things, eliminate most of the Company obligation for the further funding of NanoSynex. Pursuant to the terms of the NanoSynex Amendment, the Company lost its controlling interest in NanoSynex (see Note 5 -Discontinued Operations). Basis of Presentation The accompanying consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), Regulation S-X and rules and regulations of the Securities and Exchange Commission (“SEC”). Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its former wholly-owned and majority owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment. In general, the functional currency of the Company and its subsidiaries is the U.S. dollar. For NanoSynex, the functional currency was the local currency, New Israeli Shekels (NIS). As such, assets and liabilities for NanoSynex were translated into U.S. dollars with the effects of foreign currency translation adjustments reflected as a component of accumulated other comprehensive loss within the Company’s consolidated statements of changes in stockholders’ equity (deficit). As of July 20, 2023, NanoSynex was deconsolidated from these financial statements as the transactions contemplated by the NanoSynex Amendment resulted in a loss of control of a subsidiary that constitutes a business under ASC 810. The retained investment in NanoSynex is accounted for prospectively as an equity method investment. See Note 5 – Discontinued Operations for further information. Discontinued Operations On July 20, 2023, the Company completed the sale of Qualigen, Inc. to Chembio Diagnostics, Inc. The sale of Qualigen Inc. constituted a significant disposition and as such, the Company concluded that the disposition of ownership in Qualigen, Inc. represented a strategic shift that had a major effect on its operations and financial results. Therefore, Qualigen, Inc. is classified as discontinued operations for all periods presented herein. 39 On July 20, 2023, the Company entered into the NanoSynex Amendment, which amended the Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022, by and between the Company and NanoSynex (the “NanoSynex Funding Agreement”), a former majority owned subsidiary of the Company, to, among other things, forfeit 281,000 Series B Preferred Shares of NanoSynex held by the Company, resulting in the deconsolidation of NanoSynex. The disposition represents a strategic shift that will have a material effect on the Company’s operations and financial results. Accordingly, the business of NanoSynex is classified as discontinued operations for all periods presented herein. See Note 5 - Discontinued Operations for further information. Equity Method Investments Following deconsolidation of NanoSynex on July 20, 2023, the Company accounts for its retained investment under the equity method of accounting as it retained the ability to exercise significant influence over the operating and financial policies of the investee. Under the equity method, the Company recognizes its proportionate share earnings or losses each reporting period with an adjustment to the carrying value of the investment. As of December 31, 2023, the carrying value of the retained investment was zero, and therefore the Company has suspended application of the equity method as the Company is not liable for the obligations of the investee nor otherwise committed to provide financial support. Future equity method earnings, if any, will not be recognized until the amount exceeds the unrecognized net losses in prior periods. See Note 5 – Discontinued Operations for further information. Accounting Estimates Management uses estimates and assumptions in preparing its consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill, warrant liabilities, and stock-based compensation. Actual results could vary from the estimates that were used. Reverse Stock Split On November 23, 2022, the Company effected a 1-for-10 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split reduced the Company’s shares of outstanding common stock, stock options, and warrants to purchase shares of common stock. Fractional shares of common stock that would have otherwise resulted from the Reverse Stock Split were rounded down to the nearest whole share and cash in lieu of fractional shares was paid to stockholders. All share and per share data for all periods presented in the accompanying financial statements and the related disclosures have been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common stock and the par value per share remains unchanged. Cash The Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash equivalents. The Company maintains the majority of its cash in government money market mutual funds and in accounts at banking institutions in the U.S. that are of high quality. Cash held in these accounts often exceed the Federal Deposit Insurance Corporation (FDIC) insurance limits. If such banking institutions were to fail, the Company could lose all or a portion of amounts held in excess of such insurance limitations. In March 2023, Silicon Valley Bank and Signature Bank, and more recently in May 2023, First Republic Bank, were closed due to liquidity concerns and taken over by the FDIC. While the Company did not have an account at any of these banks, in the event of failure of any of the financial institutions where the Company maintains its cash and cash equivalents, there can be no assurance that the Company would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect the Company’s business and financial position. Impairment of Long-Lived Assets The Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between the net book value of the assets and their estimated fair values. During the years ended December 31, 2023 and 2022, no such impairment losses have been recorded. Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and managed its business as one segment operating primarily within the United States (and in Israel prior to the NanoSynex deconsolidation). 40 Research and Development Except for acquired in process research and development (IPR&D), the Company expenses research and development costs as incurred including therapeutics license costs. Patent Costs The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the consolidated statement of operations. Business Combinations The Company accounts for business combinations using the acquisition method pursuant to Financial Accounting Standards Board’s (“FASB”) ASC Topic 805. This method requires, among other things, that results of operations of acquired companies are included in the Company’s financial results beginning on the respective acquisition date, and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant. Each of these factors can significantly affect the value of the intangible asset. Any excess of the fair value of consideration transferred (the “purchase price”) over the fair values of the net assets acquired is recognized as goodwill. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred. Goodwill Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired, when accounted for using the purchase method of accounting. Goodwill has an indefinite useful life and is not amortized but is reviewed for impairment annually and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable. In testing for impairment, the fair value of the reporting unit is compared to the carrying value. If the net assets assigned to the reporting unit exceed the fair value of the reporting unit, an impairment loss equal to the difference is recorded. As a result of the annual goodwill impairment analysis, the Company recognized a $ 4,239,000 non-cash goodwill and fixed asset impairment charge in the valuation of its business acquisition of NanoSynex for the year ended December 30, 2022. Derivative Financial Instruments and Warrant Liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations and comprehensive loss. Depending on the features of the derivative financial instrument, the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period (See Note 7-Warrant Liabilities and Note 8- Convertible Debt - Related Party). Fair Value Measurements The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows: ● Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date; 41 ● Level 2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs in markets that are not considered to be active; and ● Level 3 - Inputs that are unobservable. Fair Value of Financial Instruments Cash, accounts receivable, prepaids, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Comprehensive Loss Comprehensive loss consists of net income and foreign currency translation adjustments related to the discontinued operations of NanoSynex. Comprehensive gains (losses) have been reflected in the statements of operations and comprehensive loss and as a separate component in the statements of stockholders’ equity (deficit) for all periods presented. Stock-Based Compensation Stock-based compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company’s stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in an increase to stock-based compensation expense to employees and non-employees determined at the date of grant. Income Taxes Deferred income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses, and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income in future years. For more information, refer to Note 14 - Income Taxes. In December 2023, the FASB issued Accounting Standards Update 2023-09, Improvements to Income Tax Disclosures, which requires more detailed income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is evaluating the disclosure requirements related to the new standard. Foreign Currency Translation The functional currency for the Company is the U.S. dollar. The functional currency for the discontinued operations of NanoSynex was the New Israeli Shekel (NIS). The financial statements of NanoSynex were translated into U.S. dollars using exchange rates in effect at each period end for assets and liabilities; using exchange rates in effect during the period for results of operations; and using historical exchange rates for certain equity accounts. The adjustment resulting from translating the financial statements of NanoSynex was reflected as a separate component of other comprehensive income (loss) (see Note 5 - Discontinued Operations). Recent Accounting Pronouncements The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements. 42 Global Economic Conditions Ongoing Wars in Ukraine and Israel In February 2022, Russia invaded Ukraine. While the Company has no direct exposure in Russia and Ukraine, the Company continues to monitor any broader impact to the global economy, including with respect to inflation, supply chains and fuel prices. The full impact of the conflict on the Company’s business and financial results remains uncertain and will depend on the severity and duration of the conflict and its impact on regional and global economic conditions. In October 2023, Hamas conducted terrorist attacks in Israel resulting in ongoing war. There continue to be hostilities between Israel and Hezbollah in Lebanon and Hamas in the Gaza Strip, both of which have resulted in rockets being fired into Israel, causing casualties and disruption of economic activities. In early 2023, there were a number of changes proposed to the political system in Israel by the current government which, if implemented as planned, could lead to large-scale protests and additional uncertainty, negatively impacting the operating environment in Israel. Popular uprisings in various countries in the Middle East over the last few years have also affected the political stability of those countries and have led to a decline in the regional security situation. Such instability may also lead to deterioration in the political and trade relationships that exist between Israel and these countries. Any armed conflicts, terrorist activities or political instability involving Israel or other countries in the region could adversely affect the Company’s minority interest in NanoSynex, its results of operations, financial condition, cash flows and prospects (see Note 5 – Discontinued Operations). Inflation and Global Economic Conditions During the year ended 2022 and continuing into the current fiscal year, global commodity and labor markets experienced significant inflationary pressures attributable to government stimulus and recovery programs, government deficit spending and supply chain issues. The Company cannot provide assurance that it will be successful in fully offsetting increased costs resulting from inflationary pressure. In addition, the global economy suffers from slowing growth and rising interest rates, and some economists believe that there may be a global recession in the near future. If the global economy slows, the Company’s business may be adversely affected. Impact of COVID-19 Pandemic The COVID-19 pandemic has had a dramatic impact on businesses globally and on the Company’s business as well. During the height of the pandemic, sales of diagnostic products decreased significantly and the Company’s net loss increased significantly, as clinics and small hospitals’ demand for Qualigen, Inc.’s FastPack™ diagnostic test kits was reduced sharply, largely due to deferral of patients’ non-emergency visits to physician offices. In July 2023 the Company sold Qualigen, Inc., its wholly-owned subsidiary, to Chembio (see Note 5 - Discontinued Operations). Other accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company’s consolidated financial statements. NOTE 2 — LIQUIDITY AND GOING CONCERN As of December 31, 2023, the Company had approximately $ 0.4 million in cash and an accumulated deficit of $ 116.8 million. For the years ended December 31, 2023 and 2022, the Company used cash of $ 10.3 million and $ 13.2 million, respectively, in operations. The Company’s cash balances as of the date that these financial statements were issued along with the proceeds from the above sale to Chembio, without additional financing, are expected to fund operations only into the second quarter of 2024. The Company expects to continue to have net losses and negative cash flow from operations, which will challenge its liquidity. These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the date that these financial statements were issued. 43 There is no assurance that profitable operations will ever be achieved, or, if achieved, could be sustained on a continuing basis. In order to fully execute its business plan, the Company will require significant additional financing for planned research and development activities, capital expenditures, clinical testing for QN-302 and preclinical development of Pan-RAS, as well as commercialization activities. Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred equity and proceeds from the issuance of debt. In December 2022 the Company raised $ 3.0 million from the sale of an 8% Senior Convertible Debenture (the “Debenture”) to Alpha (see Note 8 - Convertible Debt - Related Party). There can be no assurance that further financing can be obtained on favorable terms, or at all. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect the Company’s business prospects. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements do not include any adjustments that would be necessary should the Company be unable to continue as a going concern, and therefore, be required to liquidate its assets and discharge its liabilities in other than the normal course of business and at amounts that may differ from those reflected in the accompanying financial statements NOTE 3 — PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consisted of the following at December 31, 2023 and December 31, 2022: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS December 31, December 31, 2023 2022 Prepaid insurance $ 566,011 $ 1,329,034 Other prepaid expenses 25,053 37,670 Receivable from sale of Qualigen, Inc. — — Prepaid research and development expenses 173,900 — Prepaid expenses and other current assets $ 764,964 $ 1,366,704 Prepaid expenses attributable to Qualigen, Inc. and NanoSynex were deemed disposed of as discontinued operations (see Note 5 - Discontinued Operations). NOTE 4 — OTHER NON-CURRENT ASSETS Other non-current assets consisted of the following at December 31, 2023: SCHEDULE OF OTHER NON CURRENT ASSETS December 31, 2023 Funds held in escrow $ 450,000 Long-term research and development deposits 416,481 Other non-current assets $ 866,481 44 NOTE 5 — DISCONTINUED OPERATIONS The summary of assets and liabilities classified in discontinued operations as of December 31, 2022 are as follows: SCHEDULE OF BALANCE SHEETS AND INCOME STATEMENT CLASSIFIED IN DISCONTINUED OPERATIONS Qualigen, Inc. NanoSynex Total Current assets of discontinued operations $ 4,448,999 $ 1,838,850 $ 6,287,849 Non-current assets of discontinued operations 1,876,270 6,360,441 8,236,711 Total assets of discontinued operations $ 6,325,269 $ 8,199,291 $ 14,524,560 Current liabilities of discontinued operations $ 1,299,948 $ 2,141,250 $ 3,441,198 Non-current liabilities of discontinued operations 1,350,975 357,757 1,708,732 Total liabilities of discontinued operations $ 2,650,923 $ 2,499,007 $ 5,149,930 The summary of gain (loss) from discontinued operations, net of tax, as of December 31, 2023 and 2022 are as follows: Year ended December 31, 2023 Year ended December 31, 2022 Qualigen, Inc. NanoSynex Total Qualigen, Inc. NanoSynex Total (Loss) from discontinued operations $ ( 171,701 ) $ ( 511,307 ) $ ( 683,008 ) $ ( 2,142,763 ) $ ( 4,997,418 ) $ ( 7,140,181 ) Gain (loss) on disposal of discontinued operations 3,876,778 ( 4,479,010 ) ( 602,232 ) — — — Total gain (loss) from discontinued operations $ 3,705,077 $ ( 4,990,317 ) $ ( 1,285,240 ) $ ( 2,142,763 ) $ ( 4,997,418 ) $ ( 7,140,181 ) Sale of Qualigen, Inc. On July 20, 2023, the Company completed the sale of Qualigen, Inc., its formerly wholly-owned subsidiary, to Chembio Diagnostics, Inc. for net cash consideration of $ 5.4 million, of which $ 4.9 million was received during the year ended December 31, 2023, and $ 450,000 is being held in escrow until January 20, 2025 to satisfy certain Company indemnification obligations. The assets and liabilities classified in discontinued operations for Qualigen, Inc. as of December 31, 2022 are as follows: ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS December 31, 2022 Cash $ 2,246,482 Accounts receivable, net 512,088 Inventory, net 1,586,297 Prepaid expenses and other current assets 104,132 Total current assets of discontinued operations 4,448,999 Right-of-use assets 1,422,538 Property and equipment, net 289,696 Intangible assets, net 145,702 Other assets 18,334 Total non-current assets of discontinued operations 1,876,270 Total assets of discontinued operations of Qualigen, Inc. $ 6,325,269 Accounts payable $ 236,470 Accrued vacation 187,906 Accrued expenses and other current liabilities 518,766 Deferred revenue, current portion 116,161 Operating lease liability, current portion 240,645 Total current liabilities of discontinued operations 1,299,948 Operating lease liability, net of current portion 1,301,919 Deferred revenue, net of current portion 49,056 Total non-current liabilities of discontinued operations 1,350,975 Total liabilities of discontinued operations of Qualigen, Inc. $ 2,650,923 45 The Company reclassified the following statement of operations items to discontinued operations for the years ended December 31, 2023 and 2022, respectively: 2023 2022 For the Years Ended December 31, 2023 2022 REVENUES Net product sales $ 3,661,121 $ 4,983,556 Total revenues 3,661,121 4,983,556 EXPENSES Cost of product sales 2,551,114 4,302,755 General and administrative 610,559 561,047 Research and development 206,819 1,245,973 Sales and marketing 405,626 950,420 Goodwill and fixed asset impairment — 75,000 Total expenses 3,774,118 7,135,195 OTHER EXPENSE (INCOME), NET Loss on disposal of equipment held for lease 63,302 — Interest (income) expense, net — ( 7,751 ) Other expense (income), net ( 4,898 ) ( 1,125 ) Loss on fixed asset disposal 300 — Total other expense (income), net 58,704 ( 8,876 ) INCOME (LOSS) FROM DISCONTINUED OPERATIONS BEFORE DISPOSAL ( 171,701 ) ( 2,142,763 ) Gain on sale of Qualigen, Inc., net of tax 3,876,778 — INCOME (LOSS) FROM DISCONTINUED OPERATIONS OF QUALIGEN, INC. $ 3,705,077 $ ( 2,142,763 ) In connection with this transaction, the Company recorded a gain on the sale of Qualigen, Inc. in its consolidated financial statements for the years ended December 31, 2023: Gain on sale of Qualigen, Inc. Fair value of consideration received $ 5,489,337 Working capital adjustment 235,402 Total Assets of discontinued operations ( 4,225,562 ) Total Liabilities of discontinued operations 3,005,407 Transaction expenses ( 627,806 ) Gain on sale of Qualigen, Inc. $ 3,876,778 In the fourth quarter of 2023, the gain was adjusted upward by $ 17,000 upon final payment of transaction costs. Amendment and Settlement Agreement with NanoSynex Ltd. On July 20, 2023, the Company entered into and effectuated the NanoSynex Amendment, pursuant to which the Company agreed to, in exchange for eliminating all future NanoSynex Funding Agreement obligations for the Company to invest further cash in NanoSynex (except for obligations to lend NanoSynex $ 560,000 on or before November 30, 2023, and $ 670,000 on or before March 31, 2024), surrender 281,000 Series B Preferred Shares of NanoSynex held by the Company, resulting in the Company’s ownership in NanoSynex being reduced from approximately 52.8 % to approximately 49.97 % of the voting equity of NanoSynex; in addition, the Company agreed to surrender approximately $ 3.0 million of promissory notes which NanoSynex had issued to the Company under the NanoSynex Funding Agreement. On November 22, 2023, the Company further agreed to eliminate the Company’s obligations to lend NanoSynex $ 560,000 on or before November 30, 2023, and $ 670,000 on or before March 31, 2024, by instead surrendering shares of Series A-1 Preferred Stock of NanoSynex in an amount that reduced the Company’s ownership in NanoSynex voting equity from approximately 49.97 % to 39.90 %. The surrender of Series B Preferred Shares of NanoSynex was accounted for as a loss of control of a subsidiary that constitutes a business under ASC 810. As a result, on July 20, 2023, the Company deconsolidated NanoSynex’s related assets, liabilities, accumulated other comprehensive income, and the noncontrolling interest. Subsequently, the retained investment in NanoSynex is accounted for as an equity method investment. On the date of deconsolidation, the Company recognized its retained investment at fair value, which during the preparation of these financial statements was determined to be de minimis based on various economic, industry, and other factors. As a result, the Company has discontinued recognition of its proportionate share of equity method losses following the date of initial recognition. Future equity method earnings, if any, will not be recognized until the amount exceeds the unrecognized net losses in prior periods. 46 Based upon the magnitude of the disposition and because the Company is exiting certain research and development operations, the disposition represents a strategic shift that will have a material effect on the Company’s operations and financial results. Accordingly, the business of NanoSynex is classified as discontinued operations for all periods presented herein. The assets and liabilities classified in discontinued operations for NanoSynex as of December 31, 2022 are as follows: ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS December 31, 2022 Cash $ 1,621,967 Accounts receivable, net 26,499 Prepaid expenses and other current assets 190,384 Total current assets of discontinued operations 1,838,850 Restricted cash 5,690 Property and equipment, net 29,149 Intangible assets, net 5,700,000 Goodwill 625,602 Total non-current assets of discontinued operations 6,360,441 Total assets of discontinued operations of NanoSynex $ 8,199,291 Accounts payable $ 1,273 Accrued vacation 115,002 Accrued expenses and other current liabilities 293,571 R&D grant liability 780,682 Short term debt-related party 950,722 Total current liabilities of discontinued operations 2,141,250 Deferred tax liability 357,757 Total non-current liabilities of discontinued operations 357,757 Total liabilities of discontinued operations of NanoSynex $ 2,499,007 The Company reclassified the following statement of operations items to discontinued operations for the years ended December 31, 2023 and 2022, respectively: 2023 2022 For the Years Ended December 31, 2023 2022 EXPENSES Research and development $ 869,064 $ 1,105,040 Goodwill and fixed asset impairment — 4,164,000 Total expenses 869,064 5,269,040 Loss on disposal of discontinued operations 4,479,010 — (BENEFIT) PROVISION FOR INCOME TAXES ( 357,757 ) ( 271,622 ) LOSS FROM DISCONTINUED OPERATIONS ( 4,990,317 ) ( 4,997,418 ) Loss attributable to noncontrolling interest ( 343,038 ) ( 2,394,100 ) NET LOSS ATTRIBUTABLE TO STOCKHOLDERS $ ( 4,647,279 ) $ ( 2,603,318 ) 47 In connection with this transaction, the Company recorded a loss on deconsolidation of NanoSynex in its consolidated financial statements for the years ended December 31, 2023: Loss on deconsolidation of NanoSynex Fair value of NanoSynex interest retained $ — Net assets deconsolidated ( 2,768,403 ) Non-controlling interest share 1,235,443 Accumulated other comprehensive income attributable to NanoSynex 131,891 Forgiveness of debt ( 3,077,941 ) Loss from deconsolidation of NanoSynex $ ( 4,479,010 ) NOTE 6 — ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consisted of the following at December 31, 2023 and December 31, 2022: SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES December 31, December 31, 2023 2022 Board compensation $ 129,499 70,000 Interest (Convertible debt) 10,004 2,829 License fees 32,975 150,130 Payroll 1,215 1,247 Professional fees 121,775 136,203 Research and development 104,402 329,412 Vacation 151,286 165,040 Other 8,850 9,698 Accrued expenses and other current liabilities $ 560,006 $ 864,559 Other accrued liabilities attributable to Qualigen Inc, and NanoSynex were deemed disposed of as discontinued operations (see Note 5 – Discontinued Operations). NOTE 7 – WARRANT LIABILITIES In 2004, the Company issued warrants to various investors and brokers for the purchase of Series C preferred stock in connection with a private placement (the “Series C Warrants”). The Series C Warrants were subsequently extended and, upon closing of the reverse recapitalization transaction with Ritter, exchanged for warrants to purchase common stock of the Company, at $ 7.195 per share, subject to adjustment. As of December 31, 2023, the Series C Warrants had a remaining term of 0.49 years. The Series C Warrants were determined to be liability-classified pursuant to the guidance in ASC 480 and ASC 815-40, based on the inclusion of a leveraged ratchet provision for subsequent dilutive issuances. On April 25, 2022, the Series C warrants were repriced from $ 7.195 per share exercise price to $ 6.00 per share exercise price with 49,318 additional ratchet Warrants issued. On May 26, 2022, the Series C warrants were repriced from $ 6.00 per share exercise price to $ 5.136 per share exercise price with 49,952 additional ratchet Warrants issued. As a result of these repricings, 247,625 warrants were forfeited and 346,896 warrants were reissued. On December 22, 2022, the Series C Warrants were repriced again from $ 5.136 per share exercise price to $ 1.32 per share exercise price with 1,002,717 additional ratchet Warrants issued. Additionally, on December 22, 2022, in conjunction with the issuance of the Debenture to Alpha (see Note 8 – Convertible Debt – Related Party), the Company issued to Alpha a warrant to purchase 2,500,000 shares of the Company’s common stock (the “Alpha Warrant”). The exercise price of the Alpha Warrant was $ 1.65 (equal to 125 % of the conversion price of the Debenture on the closing date). The Alpha Warrant may be exercised by Alpha, in whole or in part, at any time before June 22, 2028, subject to certain terms and conditions described in the Alpha Warrant. The fair value of this warrant was included in Warrant liabilities-related party on the Company’s consolidated balance sheet as of December 31, 2022. On December 5, 2023, the Company entered into an Amendment No. 1 with regard to Securities Purchase Agreement, with Alpha. This Amendment amended two instruments which the Company issued under the Securities Purchase Agreement dated December 21, 2022: (a) the 8% Senior Convertible Debenture dated December 22, 2022 in favor of Alpha, and (b) the Common Stock Purchase Warrant dated December 22, 2022 in favor of Alpha. The Amendment reduced the conversion price of the Debenture from $ 1.32 per share to $ 0.73 per share (subject to possible future adjustment pursuant to the terms of the Debenture) and reduced the exercise price of the Warrant from $ 1.65 per share to $ 0.73 per share (subject to possible future adjustment pursuant to the terms of the Warrant). The Amendment also eliminated certain adjustment provisions of the Warrant. The Company determined the event resulted in equity classification for the Warrant and, accordingly, the Company remeasured the warrant liabilities to fair value, and reclassified. As a result of the Alpha Warrant repricing, on December 5, 2023 the Series C Warrants were repriced again from $ 1.32 per share exercise price to $ 0.73 per share exercise price with 203,652 additional ratchet Series C Warrants issued, resulting in 455,623 of these Series C Warrants outstanding and exercisable as of December 31, 2023. 48 The following table summarizes the activity in liability classified warrants for the year ended December 31, 2023: SCHEDULE OF WARRANTS ACTIVITY Common Stock Warrants Shares Weighted– Average Exercise Price Range of Exercise Price Weighted–Average Remaining Life (Years) Total outstanding – December 31, 2022 3,849,571 $ 1.53 $ 1.32 - $ 1.65 3.9 Exercised — — — — Forfeited ( 2,751,976 ) 1.53 — — Expired ( 1,097,595 ) 1.32 1.32 — Granted 455,623 0.73 0.73 0.49 Total outstanding – December 31, 2023 455,623 $ 0.73 $ 0.73 0.49 Exercisable 455,623 $ 0.73 $ 0.73 0.49 The following table summarizes the activity in the Common Stock Warrants received in exchange for the Series C Warrants for the year ended December 31, 2022: Common Stock Warrants Shares Weighted– Average Exercise Price Range of Exercise Price Weighted–Average Remaining Life (Years) Total outstanding –December 31, 2021 248,162 $ 7.20 $ 7.20 2.00 Exercised ( 536 ) 7.20 Forfeited ( 247,625 ) 7.20 Expired — — Granted 3,849,570 1.53 Total outstanding – December 31, 2022 3,849,571 $ 1.53 $ 1.32 - 1.65 3.9 Exercisable 1,349,571 $ 1.32 $ 1.32 1.00 The following table presents the Company’s fair value hierarchy for its Common Stock Warrant liabilities measured at fair value on a recurring basis as of December 31, 2023: SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES Quoted Market Significant Prices for Other Significant Identical Observable Unobservable Assets Inputs Inputs Common Stock Warrant liabilities (Level 1) (Level 2) (Level 3) Total Balance as of December 31, 2022 $ — $ — $ 3,622,647 $ 3,622,647 Exercises — — — — Fair value of warrant reclassified from liabilities to equity — — ( 1,626,694 ) ( 1,626,694 ) Loss on debt extinguishment — — 94,116 94,116 Gain on change in fair value of warrant liabilities — — ( 2,035,469 ) ( 2,035,469 ) Balance as of December 31, 2023 $ — $ — $ 54,600 $ 54,600 There were no transfers of financial assets or liabilities between category levels for the year ended December 31, 2023. The value of the warrant liabilities was based on a valuation received from an independent valuation firm determined using a Monte-Carlo simulation. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate the fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history as a public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the common stock warrant. The Company uses an expected dividend yield of zero based on the fact that the Company has never paid cash dividends and does not expect to pay cash dividends in the foreseeable future. Any significant changes in the inputs may result in significantly higher or lower fair value measurements. 49 The following are the assumptions used in, and the weighted average and the range of assumptions used in estimating the fair value of warrant liabilities (weighted average calculated based on the number of outstanding warrants on each issuance) as of December 31, 2023 and December 31, 2022: SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES December 31, 2023 December 31, 2022 Actual Range Weighted Average Risk-free interest rate 5.13 % 3.906 % — 4.628 % 4.15 % Expected volatility (peer group) 68.9 % 88 % — 103 % 98 % Term of warrants (in years) 0.49 .90 — 5.48 3.9 Expected dividend yield 0.00 % 0.00 % 0.00 % NOTE 8 — CONVERTIBLE DEBT- RELATED PARTY On December 22, 2022, the Company issued to Alpha an 8 % Senior Convertible Debenture in the aggregate principal amount of $ 3,300,000 for a purchase price of $ 3,000,000 (less expenses) pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. The Debenture has a maturity date of December 22, 2025 and was initially convertible, at any time, and from time to time, until the Debenture is no longer outstanding, at Alpha’s option, into shares of common stock of the Company (the “Conversion Shares”), at a price equal to $ 1.32 per share, subject to adjustment as described in the Debenture (the “Conversion Price”) and other terms and conditions described in the Debenture, including the necessary stockholder approvals, which the Company obtained at its 2023 annual meeting of stockholders on July 13, 2023. As a part of the same transaction, on December 22, 2022, the Company issued to Alpha a liability classified warrant (the “Alpha Warrant”) to purchase 2,500,000 shares of the Company’s common stock (see Note 7 - Warrant Liabilities). The exercise price of the Alpha Warrant was initially $ 1.65 (equal to 125 % of the Conversion Price of the Debenture on the closing date) subject to adjustment as described in the Alpha Warrant. The Alpha Warrant may be exercised by Alpha, in whole or in part, at any time before June 22, 2028, subject to certain terms and conditions described in the Alpha Warrant, including the necessary stockholder approvals, which the Company obtained at its 2023 annual meeting of stockholders on July 13, 2023. The proceeds from the transaction were used to advance the Company’s QN-302 Investigative New Drug candidate towards clinical trials and other working capital purposes. Commencing June 1, 2023 and continuing on the first day of each month thereafter until the earlier of (i) December 22, 2025 and (ii) the full redemption of the Debenture (each such date, a “Monthly Redemption Date”), the Company must redeem $ 110,000 plus accrued but unpaid interest, liquidated damages and any amounts then owing under the Debenture (the “Monthly Redemption Amount”). The Monthly Redemption Amount must be paid in cash; provided that after the first two monthly redemptions, the Company may elect to pay all or a portion of a Monthly Redemption Amount in shares of common stock of the Company, based on a Conversion Price equal to the lesser of (i) the then Conversion Price of the Debenture and (ii) 85 % of the average of the VWAPs (as defined in the Debenture) for the five consecutive trading days ending on the trading day that is immediately prior to the applicable Monthly Redemption Date. The Company may also redeem some or all of the then outstanding principal amount of the Debenture at any time for cash in an amount equal to 105 % of the then outstanding principal amount of the Debenture being redeemed plus accrued but unpaid interest, liquidated damages and any amounts then owing under the Debenture. The Company’s election to pay monthly redemptions in Conversion Shares or to effect an optional redemption is subject to the satisfaction (or waiver) of the Equity Conditions (as defined in the Debenture), including the necessary stockholder approvals, which the Company obtained at its 2023 annual meeting of stockholders on July 13, 2023. The Debenture accrues interest at the rate of 8 % per annum, which did not begin accruing until December 1, 2023. Interest may be paid in cash or shares of common stock of the Company or a combination thereof at the option of the Company; provided that interest may only be paid in shares if the Equity Conditions have been satisfied (or waived). Both the Debenture and the Alpha Warrant provide for adjustments to the Conversion Price and exercise price, respectively, in connection with stock dividends and splits, subsequent equity sales and rights offerings, pro rata distributions, and certain fundamental transactions. Both the Debenture and the Alpha Warrant include a beneficial ownership blocker of 9.99 %, which may only be waived by Alpha upon 61 days’ notice to the Company. Pursuant to resale registration rights granted by the Company to Alpha in such Securities Purchase Agreement, the Company filed a resale registration statement on Form S-3 (File Number 333-269088) on December 30, 2022 registering the resale by Alpha of up to 5,157,087 shares of common stock of the Company which could be issued to Alpha pursuant to the Debenture and the Alpha Warrant, which registration statement was declared effective by the SEC on January 5, 2023 (the “Original Registration Statement”). The Company later became ineligible to update the Original Registration Statement via incorporation by reference of its future SEC periodic and current reports as a result of its failure to timely file its annual report on Form 10-K for the fiscal year ended December 31, 2022. Therefore, the Company filed a Post-Effective Amendment No. 1 to Form S-3 on Form S-1 (No. 333-269088)(the “Post-Effective Amendment No. 1”) on September 1, 2023 in order to maintain the registration of the resale by Alpha of up to 3,958,537 shares of common stock of the Company issuable under the Debenture and the Alpha Warrant., which Post-Effective Amendment No. 1 was declared effective by the SEC on September 7, 2023. 50 The Company evaluated the Debenture and the Alpha Warrant and determined that the Alpha Warrant is a freestanding financial instrument. Initially, the Alpha Warrant is not considered indexed to the Company’s own stock, because the settlement amount would not equal the difference between the fair value of a fixed number of the Company’s equity shares and a fixed strike price and all of the adjustment features in Section 3(b) of the Alpha Warrant are not down round provisions, as defined in ASU 2017-11. Accordingly, the Alpha Warrant was classified as a liability and recognized at fair value, with subsequent changes in fair value recognized in earnings. The proceeds from the Debenture were allocated to the initial fair value of the Alpha Warrant, with the residual balance allocated to the initial carrying value of the Debenture. The Company has not elected the fair value option for the Debenture. The Debenture was recognized as proceeds received after allocating the proceeds to the Alpha Warrant, and then allocating remaining proceeds to a suite of bifurcated embedded derivative features (conversion option, contingent acceleration upon an Event of Default, and contingent interest upon an Event of Default), with the resulting difference, if any, allocated to the loan host instrument. The suite of derivative features was measured and determined to have no fair value. The original issue discount of $ 0.3 million, the initial fair value of the Alpha Warrant of $ 2.8 million, the initial fair value of the suite of bifurcated embedded derivative features of $ 0 , and the fees and costs paid to Alpha and other third parties of $ 0.1 million comprised the debt discount upon issuance. The debt discount is amortized to interest expense over the expected term of the Debenture using the effective interest method, in accordance with ASC 835-30. The debt host instrument of the Debenture will subsequently be measured at amortized cost using the effective interest method to accrete interest over its term to bring the Debenture’s initial carrying value to the principal balance at maturity. Between January 9 and 12, 2023, the Company issued 841,726 shares of common stock upon Alpha’s partial conversion of the Debenture at $ 1.32 per share for a total of $ 1,111,078 principal. Upon conversion, the Company recognized a loss on conversion of convertible debt of approximately $ 1.1 million, recorded to other expenses in the consolidated statements of operations. In October and December 2023, the Company issued 309,665 shares of common stock to Alpha in lieu of cash for monthly redemption payments on the Debenture at a weighted average price of $ 0.71 per share. Upon redemption for shares, the Company recognized a loss on partial debt extinguishment of $ 34,315 . On September 22, 2023, the Company entered into a consent and waiver (the “Waiver”) with Alpha. Pursuant to the Waiver, Alpha consented to the Company’s election to pay all of the Monthly Redemption Amount for October 2023 in Conversion Shares (the “October Payment”) and waived the requirement of satisfaction of the Equity Conditions in relation to the October and December Payment. On October 3, 2023 the Company issued 128,595 shares of common stock to Alpha in satisfaction of the October Payment. On December 8, 2023 the Company issued 181,070 shares of common stock to Alpha in satisfaction of the December Payment. On December 5, 2023, the Company and Alpha executed Amendment No. 1 with regard to Securities Purchase Agreement (the “SPA Amendment”), pursuant to which the Company and Alpha agreed to, among other things, reduce the Conversion Price of the Debenture from $ 1.32 per share to $ 0.73 per share and reduce the exercise price of the Alpha Warrant from $ 1.65 per share to $ 0.73 per share, in each case subject to certain adjustments. In addition, the SPA Amendment revised certain provisions of the Alpha Warrant to (i) limit the circumstances which would trigger a potential adjustment to the exercise price of the Alpha Warrant and (ii) clarify the treatment of the Alpha Warrant upon a Fundamental Transaction. The purpose of these revisions was to remove the terms that caused the Alpha Warrant to be liability-classified under U.S. GAAP. The Company performed an assessment and concluded that all remaining adjustment features in the revised language meet the FASB’s definition of a down-round feature. In addition, the Alpha Warrant was determined to meet all of the additional requirements for equity classification. Accordingly, as of December 5, 2023, the Company remeasured the Alpha Warrant to its fair value immediately prior to the modification and recognized the change in fair value in earnings. The incremental fair value impact from the Alpha Warrant modification of $ 0.09 million was included in the Company’s evaluation of the Debenture modification under ASC 470, discussed further below. The Company then reclassified the Alpha Warrant liability to equity at its post-modification fair value of $ 1.6 million. In accordance with ASC 470-50, the Company determined that the modified terms of the Debenture were substantially different when compared to the original terms that existed prior to the SPA Amendment, and thus the event was required to be accounted for as a debt extinguishment. Accordingly, the Company derecognized the net carrying value of the original Debenture, and recorded the new debt instrument at its fair value of $ 1.4 million, and recorded a $ 0.6 million loss on debt extinguishment. The difference between the remaining Debenture principal and its fair value on December 5, 2023 was recorded as a debt discount and will be amortized to interest expense over the expected term of the Debenture using the effective interest method, in accordance with ASC 835-30. During the year ended December 31, 2023, the Company recognized a loss on voluntary conversion of convertible debt of approximately $ 1.1 million, recognized an extinguishment loss of $ 0.6 million upon October and December 2023 share redemptions and December 2023 modification of the Debenture, and recorded accrued interest of approximately $ 1.5 million, in other expenses in the consolidated statements of operations. During the year ended December 31, 2023 the Company paid Monthly Redemption Amounts of $ 550,000 in cash and $ 220,000 in common stock, and as of December 31, 2023 the remaining Debenture principal balance was approximately $ 1.4 million, the remaining discount was approximately $ 0.1 million, and the fair value of the suite of bifurcated embedded derivative features was $ 0 . 51 The senior convertible debt comprises the following: SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT December 31, 2023 December 31, 2022 Senior convertible debenture $ 1,418,922 $ 3,300,000 Discount on convertible debenture ( 119,706 ) ( 3,239,803 ) Total convertible debt-related party $ 1,299,216 $ 60,197 As of December 31, 2023, there were no unwaived events of default or violation of any covenants under the Company’s financing obligations. NOTE 9 — EARNINGS (LOSS) PER SHARE Basic loss per share (“EPS”) is computed by dividing net loss by the weighted-average number of common shares outstanding. Diluted EPS is computed based on the sum of the weighted-average number of common shares and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of shares issuable from convertible debt, stock options and warrants. The following potentially dilutive securities have been excluded from diluted net loss per share as of December 31, 2023 and 2022 because their effect would be anti-dilutive: SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE 2023 2022 For the Years Ended December 31, 2023 2022 Net loss used for basic earnings per share $ ( 13,417,212 ) $ ( 18,640,543 ) Basic weighted-average common shares outstanding 5,072,709 3,840,340 Dilutive potential shares issuable from convertible debt, stock options and warrants — — Diluted weighted-average common shares outstanding 5,072,709 3,840,340 NOTE 10 — COMMITMENTS AND CONTINGENCIES Litigation and Other Legal Proceedings On November 9, 2021, the Company was named as a defendant in an action brought by Mediant Communications Inc. (“Mediant”) in the U.S. District Court for the Southern District of New York. The complaint alleged that Qualigen entered into an implied contract with Mediant, whereby Qualigen retained Mediant to distribute proxy materials and subsequently conduct shareholder vote tabulations. The Company filed a Motion to Dismiss with the District Court and on March 14, 2022 a hearing was held during which the presiding judge ruled in favor of the Motion to Dismiss. The Company and Mediant settled the litigation on April 5, 2022 in the amount of $ 96,558 , at which time the amount was paid. NOTE 11 — RESEARCH AND LICENSE AGREEMENTS UCL Business Limited In January 2022, the Company entered into a License Agreement with UCL Business Limited to obtain an exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug development program which had been developed at University College London, including lead and back-up compounds, preclinical data and a patent estate. (UCL Business Limited is the commercialization company for University College London.) The program’s lead compound is now being developed at the Company under the name QN-302 as a candidate for treatment for pancreatic ductal adenocarcinoma, which represents the vast majority of pancreatic cancers. The License Agreement required a $ 150,000 upfront payment, reimbursement of past patent prosecution expenses (approximately $ 160,000 ), and (if and when applicable) tiered royalty payments in the low to mid-single digits, clinical/regulatory/sales milestone payments and a percentage of any non-royalty sublicensing consideration paid to the Company. 52 For the years ended December 31, 2023 and 2022 there were license costs of approximately $ 128,000 and $ 338,000 , respectively, related to this agreement which are included in research and development expenses in the consolidated statements of operations and other comprehensive loss. QN-302 Phase 1 Study In June 2023, the Company entered into a Master Clinical Research Services Agreement with Translational Drug Development, LLC (“TD2”) whereby TD2 agreed to perform certain clinical research and development services for the Company including but not limited to trial management, side identification and selection, site monitoring/management, medical monitoring, project management, data collection, statistical programming or analysis, quality assurance auditing, scientific and medical communications, regulatory affairs consulting and submissions, strategic consulting, and/or other related services. From time to time, the Company intends to enter into statements of work with TD2 for the performance of specific services under this Master Clinical Research Services Agreement. In June 2023, the Company entered into a Master Laboratory Services Agreement with MLM Medical Labs, LLC (“MLM”) whereby MLM agreed to perform certain clinical research and development services for the Company including but not limited to laboratory, supply, testing, validation, data management, and storage services. From time to time, the Company intends to enter into work orders with MLM for the performance of specific services under this Master Laboratory Services Agreement. In June 2023, the Company entered into a Master Services Agreement with Clinigen Clinical Supplies Management, Inc. (“Clinigen”) whereby Clinigen agreed to provide certain pharmaceutical products and/or services. From time to time, the Company intends to enter into statements of work with Clinigen for the performance of specific services under this Master Services Agreement. In July 2023, pursuant to the above agreements, the Company entered into work orders and statements of work for clinical trial services for the conduct of the QN-302 Phase 1 study. The project timeline started in July 2023 and is expected to continue until approximately July 2026. The total amount to be paid under these work orders and statements of work is currently expected to be approximately $ 7.6 million over the term of the QN-302 Phase 1 study, subject to available funding. University of Louisville Research Foundation In March 2019, the Company entered into a sponsored research agreement and an option for a license agreement with University of Louisville Research Foundation, Inc. (“ULRF”) for development of several small-molecule RAS interaction inhibitor drug candidates. Under the terms of this agreement, the Company agreed to reimburse ULRF for sponsored research expenses of initially up to $ 693,000 for this program. This agreement was amended in February 2021, March 2022 and August 2023, with the current term of this agreement set to expire in December 2023 and the aggregate amount that the Company would reimburse ULRF for sponsored research expenses increased to approximately $ 2.9 million. In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the agreement, the Company took over development, regulatory approval and commercialization of the candidates from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $ 50,000 to $ 5,000,000 upon the achievement of certain regulatory and commercial milestones. Milestone payments for the first therapeutic indication would be $ 50,000 for first dosing in a Phase 1 clinical trial, $ 100,000 for first dosing in a Phase 2 clinical trial, $ 150,000 for first dosing in a Phase 3 clinical trial, $ 300,000 for regulatory marketing approval and $ 5,000,000 upon achieving a cumulative $ 500,000,000 of Licensed Product sales. The Company also must pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $ 20,000 to $ 100,000 ) for such year. Sponsored research expenses related to these RAS agreements for the years ended December 31, 2023 and December 31, 2022 were approximately $ 743,000 and $ 758,000 , respectively, and are recorded in research and development expenses in the Consolidated Statements of Operations. License costs related to these agreements for the years ended December 31, 2023 and December 31, 2022 were approximately $ 133,000 and $ 40,000 , respectively, and are included in research and development expenses in the Consolidated Statements of Operations. 53 Between June 2018 and April 2022, the Company entered into license and sponsored research agreements with ULRF for QN-247, a novel aptamer-based compound that has shown promise as an anticancer drug. Under the agreements, the Company took over development, regulatory approval and commercialization of the compound from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received a $ 50,000 convertible promissory note in payment of an upfront license fee, which was subsequently converted into the Company’s common stock, and the Company agreed to reimburse ULRF for sponsored research expenses of up to approximately $ 805,000 and prior patent costs of up to $ 200,000 . In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $ 100,000 to $ 5,000,000 upon the achievement of certain regulatory and commercial milestones. Milestone payments for the first therapeutic indication would be $ 100,000 for first dosing in a Phase 1 clinical trial, $ 200,000 for first dosing in a Phase 2 clinical trial, $ 350,000 for first dosing in a Phase 3 clinical trial, $ 500,000 for regulatory marketing approval and $ 5,000,000 upon achieving a cumulative $ 500,000,000 of Licensed Product sales. The Company also agreed to pay another $ 500,000 milestone payment for any additional regulatory marketing approval for each additional therapeutic (or diagnostic) indication. The Company must also pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $ 10,000 to $ 50,000 ) for such year. The sponsored research agreement for QN-247 expired in August 2022. The sponsored research expenses related to these QN-247 agreements for the years ended December 31, 2023 and December 31, 2022 were $ 0 and approximately $ 164,000 , respectively, and these amounts are recorded in research and development expenses in the consolidated statements of operations and other comprehensive loss. License costs related to these agreements were approximately $ 23,000 and $ 94,000 for the years ended December 31, 2023 and December 31, 2022, respectively, and are included in research and development expenses in the consolidated statements of operations and other comprehensive loss. In June 2020, the Company entered into an exclusive license agreement with ULRF for its intellectual property in the use of QN-165 as a treatment for COVID-19. Under the agreement, the Company took over development, regulatory approval and commercialization of the compound (for such use) from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $ 24,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company was required to enter into a separate sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) for at least $ 250,000 . In November 2020, the Company executed a sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) supporting up to approximately $ 430,000 in research which satisfied this requirement. This sponsored research agreement expired in November 2021 and the exclusive license agreement was terminated on October 31, 2022. There were no sponsored research expenses or license costs related to these QN-165 agreements for the years ended December 31, 2023 and 2022. NOTE 12 — STOCKHOLDERS’ EQUITY As of December 31, 2023, and 2022 the Company had two classes of capital stock: common stock and preferred stock. Common Stock Holders of common stock generally vote as a class with the holders of the preferred stock and are entitled to one vote for each share held. Subject to the rights of the holders of the preferred stock to receive preferential dividends, the holders of common stock are entitled to receive dividends when and if declared by the Board of Directors. Following payment of the liquidation preference of the preferred stock, any remaining assets will be distributed ratably among the holders of the common stock and, on an as-if-converted basis, the holders of any preferred stock upon liquidation, dissolution or winding up of the affairs of the Company. The holders of common stock have no preemptive, subscription or conversion rights and there are no redemption or sinking fund provisions. At December 31, 2023, the Company has reserved 5,781,161 shares of authorized but unissued common stock for possible future issuance as follows: SCHEDULE OF RESERVED SHARES Exercise of issued and future grants of stock options 755,715 Conversion of convertible debt 1,943,729 Exercise of stock warrants 3,081,717 Total 5,781,161 54 Preferred Stock At December 31, 2023 and December 31, 2022, there were no shares of preferred stock outstanding. Stock Options and Equity Classified Warrants Stock Options The Company recognizes all compensatory stock-based payments as compensation expense over the service period, which is generally the vesting period. In April 2020, the Company adopted the 2020 Stock Incentive Plan (the “2020 Plan”) which provides for the grant of incentive or non-statutory common stock options, restricted stock, stock bonus awards, stock appreciation rights, restricted stock units and performance awards to qualified employees, officers, directors, consultants and other service providers. At December 31, 2023 and December 31, 2022 there were 398,924 and 608,012 outstanding stock options, respectively, under the 2020 Plan and there were 356,778 and 147,690 Plan shares available, respectively, for future grant. The following represents a summary of the options granted to employees and non-employee service providers that were outstanding at December 31, 2023, and changes during the twelve months then ended: SCHEDULE OF STOCK OPTION ACTIVITY Shares Weighted–Average Exercise Price Range of Exercise Price Weighted–Average Remaining Life (Years) Total outstanding – December 31, 2022 608,012 $ 35.02 $ 5.14 - $ 51.30 8.09 Granted — — — — Expired — — — — Forfeited ( 209,088 ) 34.71 5.14 - 51.30 — Total outstanding – December 31, 2023 398,924 $ 35.21 $ 5.14 — $ 51.30 7.06 Exercisable (vested) 320,918 $ 41.97 $ 5.14 — $ 51.30 6.77 Non-Exercisable (non-vested) 78,006 $ 7.36 $ 5.14 - $ 32.90 8.36 The following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers that were outstanding at December 31, 2022, and changes during the twelve months then ended: Shares Weighted–Average Exercise Price Range of Exercise Price Weighted–Average Remaining Life (Years) Total outstanding – December 31, 2021 484,186 $ 60.70 $ 12.40 — $ 14,657.50 8.52 Granted 134,469 5.24 5.14 — 10.50 5.99 Expired ( 9,379 ) 932.75 57.50 - 14,657.50 — Forfeited ( 1,264 ) 22.64 5.14 - 49.70 — Total outstanding – December 31, 2022 608,012 $ 35.02 $ 5.14 — $ 51.30 8.09 Exercisable (vested) 288,704 $ 46.32 $ 12.40 — $ 51.30 7.59 Non-Exercisable (non-vested) 319,308 $ 24.80 $ 5.14 — $ 10.50 8.59 There was approximately $ 1.1 million and $ 5.4 million of compensation costs related to outstanding options for the year ended December 31, 2023 and December 31, 2022, respectively. This cost is expected to be recognized over a weighted average period of 1.09 years. No stock options were granted or exercised during the year ended December 31, 2023 or 2022. The exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the date of grant. The options awarded under the 2020 Plan will vest as determined by the Board of Directors but will not exceed a 10-year period. 55 There were no options granted during the year ended December 31, 2023. The weighted average grant date fair value per share of the shares underlying options granted during the year ended December 31, 2022 was $ 3.96 . Fair Value of Equity Awards The Company utilizes the Black-Scholes option pricing model to value awards under the 2020 Plan, and for equity classified compensatory warrants. Key valuation assumptions include: ● Expected dividend yield. The expected dividend is assumed to be zero, as the Company has never paid dividends and has no current plans to pay any dividends on the Company’s common stock. ● Expected stock-price volatility. The Company’s expected volatility is derived from the average historical volatilities of publicly traded companies within the Company’s industry that the Company considers to be comparable to the Company’s business over a period approximately equal to the expected term. ● Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term. ● Expected term. The expected term represents the period that the stock-based awards are expected to be outstanding. The Company’s historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of a lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method provided by the SEC. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options. The material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows: SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD For the Years Ended December 31, 2023 2022 Expected dividend yield n/a 0.00 % Expected stock-price volatility n/a 103 % Risk-free interest rate n/a 1.58 % — 3.77 % Expected average term of options (in years) n/a 5.99 Stock price n/a 5.14 - 10.50 The Company recorded stock-based compensation expense and classified it in the Consolidated Statements of Operations as follows: SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE 2023 2022 For the Years Ended December 31, 2023 2022 General and administrative $ 939,228 $ 4,649,649 Research and development 159,305 834,395 Total $ 1,098,533 $ 5,484,044 Equity Classified Compensatory Warrants In connection with the $ 4.0 million equity capital raise as part of the May 2020 reverse recapitalization transaction, the Company issued common stock warrants to an advisor and its designees for the purchase of 81,143 reverse split adjusted shares of the Company’s common stock at a reverse split adjusted exercise price of $ 11.10 per share. The issuance cost of these warrants was charged to additional paid-in capital, and did not result in expense in the Company’s consolidated statements of operations and comprehensive loss. In addition, various service providers hold equity classified compensatory warrants issued in 2017 and earlier (originally exercisable to purchase Series C convertible preferred stock, and now instead exercisable to purchase common stock) for the purchase of 66,802 reverse split adjusted shares of Company common stock at a weighted average exercise price of $ 23.40 per share. These are to be differentiated from the Series C Warrants described in Note 7- Warrant Liabilities. 56 On April 25, 2022, 60,000 warrants were repriced from $ 13.20 per share exercise price to a reverse split adjusted exercise price of $ 6.00 per share exercise price and extended from June 3, 2023 to September 14, 2023 . The increase in fair value of $ 67,370 for the modification of these warrants was charged to general and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss. These warrants expired on September 14, 2023 . On April 25, 2022 and May 26, 2022 an additional 67,620 reverse split adjusted warrants were repriced from reverse split adjusted $ 11.10 per share exercise price to $ 5.136 per share exercise price. The increase in fair value of $ 31,010 for the modification of these warrants was charged to additional paid-in capital and did not result in expense on the Company’s consolidated statements of operations and comprehensive loss. On December 22, 2022 67,620 warrants were repriced from $ 5.136 per share exercise price to $ 1.32 per share exercise price. The increase in fair value of $ 8,548 for the modification of these warrants was charged to additional paid-in capital and did not result in expense on the Company’s consolidated statements of operations and comprehensive loss. On December 5, 2023, 67,620 warrants were repriced from $ 1.32 per share exercise price to $ 0.73 per share exercise price. The increase in fair value of $ 7,945 for the modification of these warrants was charged to general and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss. No new compensatory warrants were issued during the year ended December 31, 2023 or 2022. The following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2023: SCHEDULE OF WARRANT ACTIVITY Common Stock Shares Weighted– Average Exercise Price Range of Exercise Price Weighted–Average Remaining Life (Years) Total outstanding – December 31, 2022 179,046 $ 9.12 $ 1.32 — $ 25.40 1.73 Granted to advisor and its designees — — Exercised — — Expired ( 60,000 ) 6.00 6.00 Forfeited — — Total outstanding – December 31, 2023 119,046 $ 10.69 $ 0.73 — $ 25.40 1.25 Exercisable 119,046 $ 10.69 $ 0.73 — $ 25.40 1.25 Non-Exercisable — $ — $ — — The following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2022: Common Stock Shares Weighted– Average Exercise Price Range of Exercise Price Weighted–Average Remaining Life (Years) Total outstanding – December 31, 2021 179,046 $ 15.20 $ 11.10 — $ 25.40 2.64 Granted to advisor and its designees — — Exercised — — Expired — — Forfeited — — Total outstanding – December 31, 2022 179,046 $ 9.12 $ 1.32 — $ 25.40 1.73 Exercisable 179,046 $ 9.12 $ 1.32 - $ 25.40 1.73 Non-Exercisable — $ — $ — — There was $ 7,945 in compensation costs related to outstanding warrants for the year ended December 31, 2023 and $ 67,370 for the year ended December 31, 2022. As of December 31, 2023 and December 31, 2022, there was no unrecognized compensation cost related to nonvested warrants. 57 Noncompensatory Equity Classified Warrants In May 2020, as a commitment fee, the Company issued noncompensatory equity classified warrants to Alpha (a related party) for the purchase of 27,048 reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $ 11.10 per share (of which warrants for 20,000 shares were subsequently exercised in December 2020). In July 2020 the Company issued noncompensatory equity classified warrants to Alpha for the purchase of 78,019 reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $ 0.01 per share (which were subsequently exercised in July 2020), and 192,068 reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $ 52.50 per share. In August 2020, the Company issued noncompensatory equity classified warrants to Alpha for the purchase of 128,783 reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $ 60.00 per share. In December 2020, the Company issued noncompensatory equity classified warrants to Alpha for the purchase of 100,000 reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $ 0.10 per share (which were exercised in February 2021) and 219,101 reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $ 40.70 per share. In May 2022, the Company issued noncompensatory equity classified warrants to Alpha for the purchase of 331,464 reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $ 0.01 per share. On November 29, 2021, with the exception of the warrants to purchase 27,048 reverse split adjusted shares of the Company’s common stock at a reverse split adjusted exercise price of $ 11.10 per share, the exercise prices of all outstanding warrants to purchase a total of 539,951 reverse split adjusted shares of the Company’s common stock were modified to a reverse split adjusted exercise price of $ 20.00 per share and each of their remaining terms extended by six months. The fair value of the modification cost of these warrant modifications of approximately $ 2.3 million was charged to additional paid-in capital and did not result in expense on the Company’s consolidated statements of operations and comprehensive loss. In May 2022, pre-funded warrants to purchase 331,464 reverse split adjusted shares of the Company’s common stock at a reverse split adjusted exercise price of $ 0.01 per share with no expiration date were issued to Alpha. These warrants were subsequently exercised in 2022. In conjunction with the NanoSynex Acquisition, on April 25, 2022 the exercise price of 7,048 reverse split adjusted outstanding warrants at $ 11.10 was modified to a reverse split adjusted exercise price of $ 6.00 . The increase in fair value of $ 2,533 , using a Monte Carlo pricing model for the modification of these warrants, was charged to additional paid-in capital and did not result in expense on the Company’s consolidated statements of operations and comprehensive loss. On May 26, 2022, the reverse split adjusted exercise price of these warrants was modified again to $ 5.136 , and the increase in fair value of $ 696 , using a Monte Carlo pricing model for the modification of these warrants, was included in consideration transferred in the NanoSynex Acquisition. On December 22, 2022 the exercise price of these warrants was modified again to $ 1.32 . The increase in fair value of $ 891 , using a Monte Carlo pricing model for the modification of those warrants, was charged to additional paid-in capital and did not result in expense on the Company’s consolidated statements of operations and comprehensive loss. On December 5, 2023, the Company entered into an Amendment No. 1 with regard to Securities Purchase Agreement, with Alpha. This Amendment amended two instruments which the Company issued under the Securities Purchase Agreement dated December 21, 2022: (a) the 8% Senior Convertible Debenture dated December 22, 2022 in favor of Alpha, and (b) the Common Stock Purchase Warrant dated December 22, 2022 in favor of Alpha. The Amendment reduced the Conversion Price of the Debenture from $ 1.32 per share to $ 0.73 per share (subject to possible future adjustment pursuant to the terms of the Debenture) and reduced the Exercise Price of the Alpha Warrant from $ 1.65 per share to $ 0.73 per share (subject to possible future adjustment pursuant to the terms of the Alpha Warrant). The Amendment revised certain provisions of the Warrant which resulted in reclassification of the Warrant from liabilities to equity. For more details see Note 7 - Warrant Liabilities. The following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2023: SCHEDULE OF WARRANT ACTIVITY Common Stock Shares Weighted–Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2022 547,003 $ 19.76 $ 1.32 - $ 20.00 0.33 Legacy Ritter warrants — — Reclassification of Alpha Warrant from warrant liabilities to equity 2,500,000 0.73 0.73 Exercised — — Expired ( 539,953 ) 20.00 20.00 Forfeited — — Total outstanding – December 31, 2023 2,507,050 $ 0.73 Exercisable 2,507,050 $ 0.73 0.73 4.47 Non-Exercisable — $ — $ — — 58 The following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2022: Common Stock Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2021 554,914 $ 20.10 11.10 — 37.78 1.32 Legacy Ritter warrants — — Granted 331,464 0.01 0.01 Exercised ( 331,464 ) 0.01 0.01 Expired ( 7,911 ) 37.78 37.78 Forfeited — — 0 Total outstanding – December 31, 2022 547,003 $ 19.76 1.32 - 20.00 0.33 Exercisable 547,003 $ 19.76 1.32 - 20.00 0.33 Non-Exercisable — $ — $ — — NOTE 13 — RELATED PARTY TRANSACTIONS Convertible Debt See Note 8 – Convertible Debt – Related Party for additional information concerning convertible debt – related party transactions. On December 22, 2022, the Company issued to Alpha, an 8 % Senior Convertible Debenture in the aggregate principal amount of $ 3,300,000 for a purchase price of $ 3,000,000 pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. As of December 31, 2023 the Debenture had a remaining principal balance of $ 1,418,922 , and was convertible, at any time, and from time to time, at Alpha’s option, into shares of common stock of the Company, at a price equal to $ 0.73 per share, subject to adjustment as described in the Debenture and other terms and conditions described in the Debenture. Warrants Additionally, on December 22, 2022, in conjunction with the issuance of the Debenture to Alpha, the Company issued to Alpha the Alpha Warrant to purchase 2,500,000 shares of the Company’s common stock (the “Alpha Warrant”). As of December 31, 2023, the exercise price of the Alpha Warrant was $ 0.73 . The Alpha Warrant may be exercised by Alpha, in whole or in part, at any time before June 22, 2028, subject to certain terms and conditions described in the Alpha Warrant. The Alpha Warrant is included in equity on the Company’s consolidated balance sheets (see Note 12 – Stockholders’ Equity). NanoSynex Pursuant to a Share Purchase Agreement dated April 29, 2022, the Company acquired 2,232,861 shares of NanoSynex Series A-1 Preferred Stock from Alpha in exchange for 350,000 reverse split adjusted shares of the Company’s common stock and a prefunded warrant to purchase 331,464 reverse split adjusted shares of the Company’s common stock at an exercise price of $ 0.001 per share. NOTE 14 — INCOME TAXES The following table presents domestic and foreign components of consolidated loss before income taxes from continuing operations for the periods presented: SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS December 31, 2023 December 31, 2022 Domestic $ ( 12,479,803 ) $ ( 13,887,914 ) Foreign — — Loss before provision for income taxes $ ( 12,479,803 ) $ ( 13,887,914 ) 59 A reconciliation of the statutory income tax rates and the Company’s effective tax rate is as follows: SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE December 31, 2023 December 31, 2022 Statutory federal income tax rate 21.00 % 21.00 % State taxes, net of federal tax benefit 1.76 % 7.50 % Non-deductible expenses - 0.64 % - 2.09 % NOL expiration - 5.26 % - 19.88 % Tax credit 2.92 % 3.71 % Goodwill impairment 0.00 % 0.00 % Foreign rate differential 0.00 % 0.00 % Change in fair value of warrant liability 3.35 % 0.00 % Tax impact of convertible debenture - 5.46 % 1.37 % Tax impact of divestiture - 229.26 % 4.01 % True-up - 10.65 % 2.24 % Change in valuation allowance 222.28 % - 17.91 % Income taxes provision (benefit) 0.04 % - 0.05 % Income tax expense for the year ended December 31, 2023 and 2022 consisted of the following: SCHEDULE OF PROVISION FOR INCOME TAXES December 31, 2023 December 31, 2022 For the Years Ended December 31, 2023 December 31, 2022 Current U.S. Federal $ ( 10,000 ) $ — U.S. State 5,000 7,000 Total current provision ( 5,000 ) 7,000 Deferred Benefit U.S. Federal 23,128,000 ( 236,000 ) U.S. State 4,697,000 ( 2,252,000 ) Total deferred benefit 27,825,000 ( 2,488,000 ) Change in valuation allowance ( 27,825,000 ) 2,488,000 Total provision (benefit) for income taxes $ ( 5,000 ) $ 7,000 The components of deferred tax assets and liabilities are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES December 31, 2023 December 31, 2022 Deferred tax assets: Net operating loss $ 8,644,000 $ 32,587,000 Research and development credits 4,970,000 7,857,000 Accrued expenses 68,000 1,020,000 Patent — — Stock compensation 3,004,000 3,069,000 Research and development expenses 1,102,000 1,196,000 Fixed assets — 280,000 Total deferred income tax assets 17,788,000 46,009,000 Deferred tax liabilities: Intangible assets — ( 13,000 ) Right-of-use asset — ( 382,000 ) Total deferred income tax liabilities — ( 395,000 ) Net deferred income tax assets 17,788,000 45,614,000 Valuation allowance ( 17,788,000 ) ( 45,614,000 ) Deferred tax asset, net of allowance $ — $ — 60 Based on the available objective evidence, including the Company’s history of cumulative losses, management believes it is likely that the Company’s U.S. federal and state net deferred tax assets will not be realizable. Accordingly, the Company provided for a full valuation allowance against its U.S. federal and state net deferred tax assets at December 31, 2023 and December 31, 2022. Due to the full valuation allowance already in place on the Company’s U.S. federal and state net deferred tax assets, the Company does not anticipate significant changes in the Company’s effective tax rate. However, there is no valuation allowance recorded against the Company’s foreign net operating loss deferred tax assets, as the Company’s foreign IPR&D deferred tax liabilities and foreign net operating loss deferred tax assets are both indefinite-lived and thus they may be netted to arrive at a net foreign deferred tax liability. The Tax Cuts and Jobs Act resulted in significant changes to the treatment of research or experimental (“R&E”) expenditures under Section 174. For tax years beginning after December 31, 2021, taxpayers are required to capitalize and amortize all R&E expenditures that are paid or incurred in connection with their trade or business which represent costs in the experimental or laboratory sense. Specifically, costs for U.S. based R&E activities must be amortized over five years and costs for foreign R&E activities must be amortized over 15 years; both using a midyear convention. The Company has incorporated the impact of this new tax legislation into its 2023 and 2022 consolidated financial statements, noting that the impact on the Company’s consolidated financial statements was immaterial. At December 31, 2023, the Company has U.S. federal and state net operating loss carryforwards of approximately $ 15,942,000 and $ 78,693,000 , respectively, which are available to offset future taxable income. U.S. federal and state net operating loss carryovers began to expire in 2020. As a result of the May 2020 reverse recapitalization, an ownership change has occurred. The Company has not completed an Internal Revenue Code Section 382 analysis. As a result, there could be substantial limitations on the Company’s ability to utilize its pre-ownership change net operating loss and tax credit carryforwards. These substantial limitations may result in both a permanent loss of certain tax benefits related to net operating loss carryforwards and federal research and development credits, and an annual utilization limitation. The Company also has research and development credit carryforwards for federal and state tax purposes of approximately $ 3,560,000 and $ 1,410,000 , respectively. The research and development credit carryforwards began to expire in 2020 for federal tax purposes and have an indefinite life for state tax purposes . U.S. income tax has not been recognized on the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries that is indefinitely reinvested outside the United States. This amount becomes taxable upon a repatriation of assets from the subsidiary or a sale or liquidation of the subsidiary. Determination of the amount of any unrecognized deferred income tax liability on this temporary difference is not practicable because of the complexities of the hypothetical calculation. The Company files income tax returns in the U.S. federal jurisdiction and in various states. The Company’s U.S. federal income tax returns remain subject to examination by the Internal Revenue Service. The Company’s California income tax returns remain subject to examination by the California Franchise Tax Board. Due to net operating losses, research and development credits and other tax credit carryforwards that may be utilized in future years, all U.S. federal and state tax years are open to examination. Generally accepted accounting principles clarify the accounting for uncertainty in income taxes recognized in the Company’s financial statements and prescribe thresholds for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provide guidance on de-recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company adopted these provisions effective April 1, 2009. The Company did no t have any unrecognized tax benefits as of December 31, 2023 and December 31, 2022 and does not expect this to change significantly over the next 12 months. In accordance with generally accepted accounting principles, the Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. As of December 31, 2023, the Company has not accrued any interest or penalties related to uncertain tax positions. NOTE 15 — SUBSEQUENT EVENTS On February 26, 2024, the Company entered into a Securities Purchase Agreement (“Agreement”) with Alpha. The transactions contemplated by the Agreement closed on February 27, 2024, at which time the Company delivered to Alpha the 2024 Debenture and the 2024 Warrant, as described below, and Alpha paid the Company a cash purchase price of $ 500,000 (less $ 25,000 for expense reimbursement). Pursuant to the Agreement, the Company issued to Alpha an 8% Convertible Debenture (the “2024 Debenture”) in the principal amount of $ 550,000 . The Debenture has a maturity date of December 31, 2024 and is convertible, at any time, and from time to time, at Alpha’s option, into shares of common stock of the Company, at $ 0.6111 per share, subject to adjustment as described in the 2024 Debenture (the “Conversion Price”). The Debenture accrues interest on its outstanding principal balance at the rate of 8 % per annum. The 2024 Debenture does not call for scheduled payments of principal or interest before the scheduled maturity date of December 31, 2024. Pursuant to the terms of the Agreement, the Company also issued to Alpha a 5-year common stock purchase warrant (the “2024 Warrant”) to purchase (at $ 0.26 per share) 900,016 shares of common stock of the Company. Under the Agreement, Alpha also has an option, exercisable until July 1, 2024, to purchase from the Company up to an additional $ 1,100,000 in principal amount of 2024 Debentures of like tenor, together with up to an additional 1,800,032 2024 Warrants of like tenor, which would (if and when Alpha exercises such option) provide us up to an additional $ 1.0 million in cash proceeds (less expense reimbursement, and not including any possible cash proceeds from any future exercise of the additional 2024 Warrants). We granted Alpha “piggyback” registration rights for the common shares underlying the 2024 Debenture and the 2024 Warrant. 61 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. Not applicable.